Skip to main content
Terug
EWTX logo

Edgewise Therapeutics, Inc.

Datakwaliteit: 100%
EWTX
NASDAQ Healthcare Biotechnology
€ 29,80
▲ € 0,74 (2,55%)
Marktkapitalisatie: 3,20B
Dagbereik
€ 28,90 € 30,33
52-Weeksbereik
€ 10,60 € 31,82
Volume
696.023
50D / 200D Gem.
€ 28,95 / € 19,99
Vorige Slotkoers
€ 29,06

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -19,1 0,4
P/B 6,1 2,9
ROE % -34,2 3,7
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 38,67 +29.8%
Low: € 25,00 High: € 46,00
Forward WPA
-€ 2,09
Omzet Sch.
2,3 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,31
€ 0,61 – € 2,30
780 M 5
FY2029 -€ 0,77
-€ 1,35 – -€ 0,36
340 M 2
FY2028 -€ 1,72
-€ 2,31 – -€ 1,20
130 M 7

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -143,82M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-34,19%
ROIC-27,28%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,01
Current Ratio19,85
Interest Coverage0,00

Waardering

P/E Ratio
-19,05
P/B Ratio6,12
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -167,80M
ROE -34,19% ROA -30,36%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -143,82M
ROIC -27,28% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 19,85
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -19,05 P/B Ratio 6,12
P/S Ratio N/A PEG Ratio -1,23
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 3,20B Enterprise Value 3,14B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -167,80M -133,81M -100,16M -67,64M -42,81M
EPS (Diluted) -1,63 -1,45 -1,57 -1,26 -0,86
Gross Profit -2,27M 0,0 0,0 0,0 0,0
Operating Income -191,41M -158,83M -114,36M -71,66M -43,22M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 552,60M 486,82M 340,04M 367,10M 285,23M
Total Liabilities 30,35M 27,60M 21,21M 20,39M 10,85M
Shareholders' Equity 522,26M 459,22M 318,83M 346,72M 274,38M
Total Debt 3,99M 4,74M 5,41M 4,41M 0,0
Cash & Equivalents 61,15M 41,67M 86,10M 21,99M 15,57M
Current Assets 543,39M 475,48M 327,00M 357,00M 283,77M
Current Liabilities 27,37M 23,86M 16,77M 16,59M 10,52M